tex

tex analyzes RNA sequencing–derived multi-omics data from 624 lung squamous cell carcinoma (LUSC) samples to identify tumor microenvironment immune profiles and biomarkers associated with immune checkpoint blockade (ICB) resistance.

Key Features:

• Unsupervised Clustering Analysis: Employs unsupervised clustering techniques to define distinct gene expression patterns in the tumor microenvironment.
• Correlation with Immune Signatures: Correlates expression patterns with T cell exhaustion signatures and immunosuppressive cell markers including M2 macrophages and CD4+ regulatory T cells (Tregs).
• Identification of Exhausted Immune Class (EIC): Defines an Exhausted Immune Class characterized by enrichment of T cell exhaustion signatures and upregulation of inhibitory checkpoints CTLA4, PDCD1, LAG3, BTLA, TIGIT, HAVCR2, IDO1, SIGLEC7, and VISTA, alongside increased anti-inflammatory cytokines TGFβ and CCL18.
• Predictive 167-gene Biomarker Signature: Provides a 167-gene signature that predicts ICB resistance in LUSC and has potential applicability to other cancers such as melanoma.
• Validation with Internal and External Datasets: Validates findings using both internal and external datasets to assess robustness of identified biomarkers and classes.
• Distinct Methylation Patterns and Chromosomal Alterations: Characterizes EIC by distinct methylation patterns and a lower chromosomal alteration burden.
• Multi-omics RNA Sequencing Dataset: Operates on multi-omics analyses derived from RNA sequencing of 624 LUSC samples.

Scientific Applications:

• ICB Resistance Mechanism Studies: Dissects molecular and cellular features of ICB resistance in LUSC by defining immune-exhausted tumor microenvironment states.
• Biomarker-guided Patient Stratification: Enables stratification of patients for immunotherapy using the 167-gene predictive signature and immune class assignment.
• Target Discovery for Immunotherapy: Identifies upregulated inhibitory checkpoints and cytokines as candidate therapeutic targets in immunosuppressive tumors.
• Epigenetic and Genomic Context Analysis: Links methylation patterns and chromosomal alteration burden to immune-exhausted phenotypes for integrated genomic-epigenetic studies.

Methodology:

Analysis of RNA sequencing–derived multi-omics data from 624 LUSC samples; unsupervised clustering; correlation analyses with T cell exhaustion signatures and immunosuppressive cell markers; enrichment and expression analyses for inhibitory checkpoints and cytokines to define the EIC; derivation of a 167-gene predictive signature; validation on internal and external datasets; characterization of methylation patterns and chromosomal alteration burden.